GlassScriptPhysician profile
Frank Joseph Amico
NPI 1841298064
$8,466.78
in general payments reported to CMS, 2019-2025
35 companies · $98.80 in 2025
The $98.80 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,411 · 2020: $5,561 · 2021: $1,065 · 2022: $182 · 2023: $46.62 · 2024: $103 · 2025: $98.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $248.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Ab | $3,435.74 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $1,636.56 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $334.76 | 2019-2024 | Jardiance |
| Pfizer INC. | $271.92 | 2019-2021 | |
| Abbvie INC. | $228.93 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $218.81 | 2019-2021 | |
| Glaxosmithkline, LLC. | $214.61 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $205.79 | 2019-2021 | |
| Boston Scientific Corporation | $182.12 | 2022 | |
| Amarin Pharma, INC. | $173.31 | 2019-2021 | |
| Indivior INC. | $162.89 | 2019-2021 | |
| Novo Nordisk INC | $131.56 | 2019-2021 | |
| Biotronik INC. | $127.75 | 2023-2025 | Zero Gravity, Acticor 7 Vr-T Dx, Selectra |
| Amgen INC. | $119.17 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $118.83 | 2019-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $118.39 | 2019 | |
| Janssen Pharmaceuticals, INC | $104.42 | 2019-2021 | |
| Edwards Lifesciences Corporation | $82.33 | 2025 | Sapien 3 Ultra Resilia |
| Radius Health, INC. | $76.96 | 2020-2021 | |
| Abbott Laboratories | $65.22 | 2019 | |
| Novartis Pharmaceuticals Corporation | $62.11 | 2019-2021 | |
| Allergan, INC. | $51.68 | 2019-2020 | |
| Esperion Therapeutics, INC. | $49.54 | 2020-2021 | |
| Lilly USA, LLC | $45.25 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $34.86 | 2019 | |
| Mylan Specialty L.P. | $33.82 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $30.26 | 2019-2020 | |
| Astellas Pharma US INC | $29.73 | 2019 | |
| Livanova USA, INC. | $23.23 | 2023 | Tandemlife |
| Althera Pharmaceuticals LLC | $20.03 | 2021 | |
| Orexo US, INC. | $19.50 | 2019 | |
| Genentech USA, INC. | $16.18 | 2019 | |
| Mdd US Operations, LLC | $14.24 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.20 | 2021 | |
| Irhythm Technologies, INC. | $12.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Amico listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.